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Abstract
Several lines of evidence suggest a role for dopamine in the control of suicidal behaviour.
Previously, we suggested an involvement of D2-dopaminergic function in the biology of suic-
ide by demonstrating a smaller growth hormone (GH) response to apomorphine, a dopami-
nergic agonist, in depressed patients who later died by suicide. The purpose of the present
study was to assess GH response to apomorphine in major depressed in-patients with a history
of highly lethal suicide attempt compared to depressed patients with a low lethal lifetime
suicide attempt history and non-attempters. The study was performed in a sample of 26 male
depressed in-patients with a history of suicide attempt compared to 26 male depressed non-
attempters. We observed a significant difference between suicide attempters and non-attempters
(for GH peak, 6.3±5.1 ng/ml vs 15.8±14.2 ng/ml, F=10.3, df=1, 50, P=0.002). Moreover, GH
peak responses to apomorphine did not differ between depressed patients with a high lethal
lifetime suicide attempt history and patients who made low lethal lifetime suicide attempt. In
conclusion, the results of the present study support a role for dopamine in the biology of
suicidal behaviour. More specifically, an impaired GH response to apomorphine could be a
marker of suicide risk.  2001 Elsevier Science Ltd. All rights reserved.
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1. Introduction
An impaired serotonergic activity has been extensively observed in different psy-
chiatric diagnostic categories such as depression, anxiety, schizophrenia, alcoholism
and personality disorders. Suicidal dimension could be a common link between these
psychiatric disorders. Indeed, suicidality has been associated with low cerebrospinal
fluid 5-hydroxyindolacetic acid (5-HIAA) concentration across several diagnostic
entities in a large number of studies (Asberg, 1997). The role of serotonin as a
biological correlate of suicidal behavior has also been proposed in post-mortem,
platelet and neuroendocrine studies, but with some inconsistent results (Pandey,
1997; Mann and Stoff, 1997). A reduced serotonergic function has been consistently
observed in patients with a history of high-lethality suicide attempt or in those with
a high level of impulsivity (Mann and Malone, 1997).
The role of the dopaminergic system has been less extensively evaluated. Post-
mortem studies have provided conflicting results. In 1984, Crow et al. reported an
increase in homovanillic acid (HVA) concentration in the hippocampus, but not the
cortex, of suicide victims. Ohmori et al. (1992) observed an increase in HVA concen-
trations in the frontal cortex of individuals who committed suicide compared to sub-
jects who died by a physical illness. Bowden et al. (1997) provided results supporting
reduced dopamine turnover in depressed suicides by demonstrating decreased dihyd-
roxyphenylacetic acid (DOPA) in the basal ganglia of suicide completers who died
by non-violent means. In contrast, Arranz et al. (1997) did not find any difference
in cortical HVA concentrations between suicide victims and controls. Several studies
assessing dopaminergic function by measuring CSF dopaminergic metabolites in
suicide attempters have suggested an association between dopamine hypoactivity and
suicidality. Low levels of CSF HVA have been found in depressed patients with a
history of either violent or non-violent suicide attempts than in controls (reviewed
by Engstro¨m et al., 1999). In a five year longitudinal study, Roy et al. (1989)
observed that patients who reattempted suicide during the follow-up period had lower
CSF HVA concentrations compared to controls. This predictive value of low CSF
HVA concentrations has been confirmed in another longitudinal study over a period
of two years (Tra¨skman-Bendz et al., 1993). Recently, Engstro¨m et al. (1999) showed
reduced CSF HVA concentrations and HVA/5–HIAA ratios in suicide attempters
compared to controls. Moreover, it has been suggested that low CSF HVA concen-
trations could be a more reliable index of suicidal behavior than low CSF 5–HIAA
(Roy et al., 1986). In contrast, Mann and Malone (1997) did not find any association
between CSF HVA concentrations and suicidality in depressed suicide attempters
with a high degree of lethality. Mann and Malone emphasized that suicide attempt is
a complex dimension compared to suicide completion. Indeed, some suicide attempts
generally called failed suicide involve a real intent to die and are frequently associa-
ted with significant medical damage and the use of high lethality methods, whereas
other attempts called “parasuicide” involve little medical damage and low lethality
methods. In fact, both categories are parts of a large spectrum of suicidal behaviour.
In this context, studies assessing biological correlates of suicidal behavior should
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take account of the real nature of suicide attempt and in paticular the real lethality
of the attempt.
In 1992, we suggested an involvement of D2-dopaminergic function in the
expression of suicidal behavior by demonstrating a smaller growth hormone (GH)
response to apomorphine, a dopaminergic agonist, in depressed patients with a his-
tory of suicide attempts in comparison to non-attempters (Pitchot et al., 1992). More
recently, we confirmed this observation in a sample of non-depressed suicide
attempters (Pitchot et al, personal results) and in major depressed patients who died
by suicide within one year of neuroendocrine assessment (Pitchot et al., 2001). The
purpose of the present study was to assess GH response to apomorphine in major
depressed in-patients with a history of highly lethal suicide attempt compared to
depressed patients with a low lethal lifetime suicide attempt history and non-
attempters. We also controlled some confounding factors such as gender, age, sever-
ity of depression, and level of psychomotor retardation.
2. Methods
2.1. Subjects
The study was performed in a sample of 26 male in-patients fulfilling DSM–IV
(APA, 1994) criteria for major depressive disorder. Patients had a mean age±SD of
41.6±13.2 years. Diagnostic assessments were performed by two clinical and research
psychiatrists (WP and AGM). Patients were individually matched for age (within
three years) with 26 major depressed male in-patients with no history of suicidal
behavior. Due to the influence of estrogens on hormonal responses, women were
excluded from the study. We also excluded patients with psychotic symptoms or a
diagnosis of schizotypic personality disorder. Both groups included one bipolar
patient. Diagnosis of melancholia was present in seven patients in the suicide
attempters group and in nine subjects in the control goup. Overweight (35% above
the ideal body weight) patients were excluded from the study. Moreover, there was
no significant difference in mean weight between both groups. All patients had a
score of at least 15 on the 21-item Hamilton depression scale (Hamilton, 1960) at
the end of a drug-free period of at least two weeks (five weeks in case of fluoxetine
prescription) during which patients were only allowed occasional low doses of
benzodiazepines if necessary.
Past history of suicide attempt was based on interviews of the patient and their
family. The lethality of the attempt was assessed using the SADS lethality scale
(Spitzer and Endicott, 1977) refering to the most lethal lifetime suicide attempt.
Suicide attempters were divided into high-lethality (score 4, mean±SD=5.3±0.7,
1.6 attempts) and low-lethality (score 4, mean±SD=2.6±0.5, 1.2 attempts) suicide.
The time interval between the most lethal suicide attempt and the neuroendocrine
test ranged from two to 150 weeks (mean±SD=27.9±46.9 weeks).
All patients were free of medical illness as evidenced by history, medical examin-
ation, electrocardiogram, chest X-ray, electroencephalogram, and routine laboratory
692 W. Pitchot et al. / Psychoneuroendocrinology 26 (2001) 689–696
tests. Patients with a basal systolic blood pressure less than 100 mm Hg were
excluded from the study. Moreover, in order to be included, patients had to present
a basal (t0) GH level less than 5 ng/ml before the pharmacological challenge. The
exclusion of subjects with basal GH values 5 ng/ml is recommended because “pre-
stimulator” healthy volunteers tend to respond significantly less to a noradrenergic
challenge than healthy volunteers with low basal values (Laakmann, 1990). Finally,
patients gave informed consent for their participation in neuroendocrine studies at
the University Hospital of Lie`ge, Belgium.
2.2. Neuroendocrine test procedure
The apomorphine test was performed at bedrest after an overnight fast. At 0700
h, an indwelling catheter was inserted in a forearm vein. Blood samples of 10 ml
were collected at 20, 0, +20, 40, 60 and 120 min after injection at 0800 h of
apomorphine (0.5 mg diluted in saline to obtain 0.5 ml) subcutaneously.
GH was measured with a double antibody radioimmunoassay (Franchimont, 1968),
with intra-assay and inter-assay coefficients of variation of, respectively, 13.3±4.7%
and 14.8±9.6% and a detection limit of 0.2 ng/ml.
The cut-off GH peak following apomorphine was defined as 5 ng/ml (Ansseau et
al., 1984). In a previous study, all seven controls (100%) tested with apomorphine
(0.5 mg) presented GH responses higher than 5 ng/ml (Rotrosen et al., 1976). More
recently, in a sample of 12 normal volunteers, we observed GH responses above 5
ng/ml in 11 of 12 (92%) subjects. Moreover, individual peaks following apomorphine
(0.75 mg) were higher than 5 ng/ml in 114 of 121 (94%) normal subjects (reviewed
by Ansseau et al., 1982).
2.3. Data analysis
GH responses to apomorphine were measured by GH peak values following injec-
tion. Analyses were performed using absolute GH values as well as differences
related to basal (t0) levels (relative values). Since the correlation between absolute
and relative values were very high (r0.98), only absolute values are reported here.
Moreover, since peak and area under the curve values are generaly highly correlated
(r0.97), we decided to choose GH peak values as the measure of maximal hormonal
response to apomorphine. Comparisons between groups used analysis of variance
(ANOVA) or covariance when necessary. We also used Pearson’s correlation coef-
ficient and chi-square procedure.
3. Results
We did not observe any statistically significant difference between groups for
HAMD scores (26.2±7.2 in suicide attempters vs 23.5±5.1 in non-attempters, F=2.5,
df=1, 50, P=0.12). GH was not correlated with age (r=0.18, P=0.21) or psychomo-
tor retardation sub-scale scores of the HAMD (r=0.11, P=0.43). Mean GH peak
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responses to apomorphine differed significantly between suicide attempters and non-
attempters (mean±SD): for GH peak, 6.3±5.1 ng/ml vs 15.8±14.2 ng/ml, F=10.3,
df=1, 50, P=0.002 (Fig. 1). Adding age, HAMD and psychomotor retardation sub-
scale scores in an ANCOVA set-up only decreased the F-value from 10.3 to 9.8
(P=0.003). Thirteen of the 26 (50%) patients with a history of suicide attempts exhib-
ited a blunted GH response to apomorphine compared to 6 of 26 (23%) non-
attempters (chi square=4.06, df=1, P=0.04). Moreover, time interval between the
most lethal suicide attempt and the neuroendocrine test was not correlated with GH
responses (r=0.36, P=0.15).
We did not observe any statistically significant differences between high lethality
(n=14) and low lethality (n=12) suicide attempters for age (F=3.61, P=0.07), HAMD
scores (F=0.43, P=0.51), psychomotor retardation subscale scores of HAMD
(F=3.11, P=0.09) and diagnosis of melancholia (F=1.15, P=0.29). Mean GH peak
responses to apomorphine did not differ between depressed patients with a high lethal
lifetime suicide attempt history and patients who made low lethal lifetime suicide
attempt: for GH peak, 5.6±3.1 ng/ml vs 7.0±6.8 ng/ml, F=0.43, df=1, 24, P=0.51.
An ANCOVA analysis with age, melancholia, HAMD and HAMD psychomotor
retardation subscales scores as covariates decreased the F-value from 0.43 to 0.13
(P=0.72). Moreover, we did not observe any significant correlation between GH
responses to apomorphine and SADS lethality scores (r=0.08, P=0.71).
4. Discussion
Our results are consistent with the role of the dopaminergic system, and in parti-
cular of D2-receptors, in the biology of suicidal behavior. Indeed, male depressed
Fig. 1. GH responses to apomorphine in suicide attempters (SA) compared to nonattempters (NSA)
(F=10.3, df=1, 50, P=0.002).
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suicide attempters exhibited a blunted GH response to apomorphine compared to
depressed controls who never attempted suicide. Moreover, we did not observe any
significant difference between high and low lethality suicide attempters suggesting
that both groups could share some biological disturbances, and in particular at the
level of the dopaminergic system.
The results of the present study are in agreement with our previous studies in
which we demonstrated an impaired GH response to apomorphine in depressed and
non-depressed suicide attempters compared to non-attempters (Pitchot et al., 1992).
Several studies assessing CSF HVA levels in suicide attempters have also suggested
a relationship between suicidality and dopaminergic function (Engstro¨m et al., 1999).
However, these indirect measures of dopamine activity could be much more in
relationship with the depressive spectrum rather than with the suicidal dimension.
Indeed, decrease in CSF HVA levels is frequently observed in CSF studies (Goodwin
and Jamison, 1990). In 1981, Tra¨skman-Bendz et al. observed low CSF HVA con-
centrations in depressed suicide attempters, but not in attempters with other psychi-
atric diagnosis compared to controls. In fact, most studies reporting an association
between measures of dopamine function and suicidal dimension are performed in
depressed patients or in heterogenous samples of psychiatric patients. In fact, dopam-
inergic hypoactivity in suicide attempters could be in relationship with some psycho–
social risk factors related to suicidal behavior rather than with diagnosis as such.
Our results have to be taken with caution due to the small sample size and to
the lack of specific assessment of impulsivity, impulsive aggression and Cluster B
Personality Disorder co-morbidity. Moreover, a confounding factor is the possible
influence of antidepressant treatment on GH response to apomorphine. Indeed, sev-
eral reports have suggested that tricyclics may impair the GH response to clonidine
for periods longer than three weeks following discontinuation (Schittecatte et al.,
1989). However, previously, we assessed the GH response to apomorphine in 11
male DSM–III–R major depressive inpatients who had never received antidepressant
therapy compared with 11 normal controls and 11 major depressive in-patients drug-
free for at least two weeks, and demonstrated that a wash-out period of two weeks
was sufficient to assess GH response to apomorphine (Pitchot et al., 1995). Another
problem is that the GH response to apomorphine provides information about the
sensitivity of D2 receptors at the hypothalamic level and we do not know to what
extent a hypothalamically mediated endocrine response is informative about the
dopaminergic function in mesocortical and mesolimbic systems. Despite these limi-
tations, the apomorphine test remains a very interesting technique for investigating
dopaminergic system providing an indirect approach of the functional state of the
dopaminergic system in vivo. In comparison, CSF concentration of HVA is a weak
indicator of central dopaminergic function providing information on presynaptic but
not postsynaptic activity. CSF studies are unable to state if the decreased in DA
turnover is a consequence of dopaminergic cell loss, a diminished availability of
tyrosine in the cell, presynaptic or postsynaptic receptors dysfunction, and therefore
to determine which type of receptor is involved in suicidal behaviour. Moreover,
lumbar puncture necessary for CSF analysis is a very invasive technique, not so
easy to use in clinical practice. Therefore, taking account of some limitations, the
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apomorphine test could be considered as a possible biological marker of suicidal
behaviour in affective disorders and help the clinician in the assessement of suic-
ide risk.
In conclusion, the results of the present study support a role for dopamine in
the biology of suicidal behavior. More specifically, an impaired GH response to
apomorphine could be a marker of suicide risk. However, several methodological
problems should be studied to improve the real utility of the apomorphine test in
clinical practice.
References
American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th ed.
APA, Washington, DC.
Ansseau, M., Doumont, A., Legros, J.J., 1982. Evidence for a catecholaminergic deficiency in primary
depression by means of specific neuroendocrine tests. Presented at the joint meeting of the Association
Franc¸aise de Psychiatrie Biologique and of the British Association for Psychopharmacology, Paris.
Ansseau, M., Scheyvaerts, M., Doumont, A., Poirrier, R., Legros, J.J., Franck, G., 1984. Concurrent use
of REM latency, dexamethasone suppression, clonidine, and apomorphine tests as biological markers
of endogenous depression: a pilot study. Psychiat Res. 12, 261–272.
Arranz, B., Blennow, K., Eriksson, A., Mansson, J.E., Marcusson, J., 1997. Serotonergic, noradrenergic,
and dopaminergic measures in suicide brains. Biol. Psychiatry 41, 1000–1009.
Asberg, M., 1997. Neurotransmitters and suicidal behavior: the evidence from cerebrospinal fluid studies.
Ann. N.Y. Acad. Sci. 836, 158–181.
Bowden, C., Cheetham, S.C., Lowther, S., Katona, C.L.E., Crompton, M.R., Horton, R.W., 1997. Reduced
dopamine turnover in the basal ganglia of depressed suicides. Brain Res. 769, 135–140.
Crow, T.J., Cross, A.J., Cooper, S.J., Deakin, J.F., Ferrier, I.N., Johnson, J.A., Joseph, M.H., Owe, F.,
Poulter, M., Lofthouse, R., 1984. Neurotransmitter receptors and monoamine metabolites in the brains
of patients with Alzheimer-type dementia and depression and suicides. Neuropsychopharmacology 23,
1561–1569.
Engstro¨m, G., Alling, C., Blennow, K., Regne´ll, G., Tra¨skman-Bendz, L., 1999. Reduced cerebrospinal
HVA concentrations and HVA/5–HIAA ratios in suicide attempters. Monoamine metabolites in 120
suicide attempters and 47 controls. Eur. Neuropsychopharmacol. 9, 399–405.
Franchimont, P., 1968. Le dosage radioimmunologique de l’hormone de croissance humaine. Cah. Med.
Lyonnais 44, 887–898.
Goodwin, F.K., Jamison, K.R., 1990. In: Manic-Depressive Illness. Oxford University Press, New York
and Oxford, pp. 416–502.
Hamilton, M., 1960. A rating scale for depression. J. Neurol. Neurosurg. Psychiat. 23, 56–62.
Laakmann, G., 1990. Psychopharmacoendocrinology and Depression Research. Springer-Verlag, Berlin.
Mann, J.J., Malone, K.M., 1997. Cerebrospinal fluid amines and higher-lethality suicide attempts in
depressed inpatients. Biol. Psychiatry 41, 162–171.
Mann, J.J., Stoff, D.M., 1997. A synthesis of curent findings regarding neurobiological correlates and
treatment of suicidal behavior. Ann. N.Y. Acad. Sci. 836, 352–363.
Ohmori, T., Arora, R.C., Meltzer, H.Y., 1992. Serotonergic measures in suicide brain: the concentration
of 5-HIAA, HVA, and tryptophan in frontal cortex of suicide victims. Biol. Psychiatry 32, 57–71.
Pandey, G.N., 1997. Altered serotonin function in suicide: evidence from platelet and neuroendocrine
studies. Ann. N.Y. Acad. Sci. 836, 182–200.
Pitchot, W., Hansenne, M., Gonzalez Moreno, A., Ansseau, M., 1992. Suicidal behavior and growth
hormone response to apomorphine test. Biol. Psychiatry 31, 1213–1219.
Pitchot, W., Hansenne, M., Gonzalez Moreno, A., Ansseau, M., 1995. Effect of previous antidepressant
therapy on the growth hormone response to apomorphine. Neuropsychobiology 32, 19–22.
696 W. Pitchot et al. / Psychoneuroendocrinology 26 (2001) 689–696
Pitchot, W., Reggers, J., Pinto, E., Hansenne, M., Fuchs, S., Pirard, S., Ansseau, M., 2001. Reduced
dopaminergic activity in depressed suicides. Psychoneuroendocrinology 26, 331–335.
Rotrosen, J., Angrist, B.M., Gershon, S., Sachar, E.J., Halpern, F.S., 1976. Dopamine alteration in schizo-
phrenia: neuroendocrine evidence. Psychopharmacology 51, 1–7.
Roy, A., Agren, H., Pickar, D., Linnoila, M., Doran, A.R., Cutler, N.R., Paul, S.M., 1986. Reduced
CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindolacetic acid ratios
in depressed patients: relationship to suicidal behavior and dexamethasone nonsuppression. Am. J.
Psychiatry 143, 1539–1545.
Roy, A., De Jong, J., Linnoila, M., 1989. Cerebrospinal fluid monoamine metabolites and suicidal behavior
in depressed patients: a 5-years follow-up study. Arch. Gen. Psychiatry 46, 609–612.
Schittecatte, M., Charles, G., Machowski, R., Wilmotte, 1989. Tricyclic wash-out and growth hormone
response to clonidine. Br. J. Psychiatry 154, 858–863.
Spitzer, R.L., Endicott, J., 1977. Schedule for Affective Disorders and Schizophrenia (SADS), 3rd ed.
New York State Psychiatric Institute, Biometrics Research, New York.
Tra¨skman-Bendz, L., Asberg, M., Bertilsson, L., Sjo¨strand, L., 1981. Monoamine metabolites in CSF and
suicidal behavior. Arch. Gen. Psychiatry 38, 631–636.
Tra¨skman-Bendz, L., Alling, C., Alse´n, M., Regne´ll, G., Simonsson, P., O¨ hman, R., 1993. The role of
monoamines in suicidal behavior. Acta Psychiatr. Scand. 371 (Suppl.), 45–47.
